Efficacy of dupilumab reveals therapeutic target for IgG4-related disease: simultaneous control of inflammation and fibrosis. Yamamoto M, Yoshikawa N, Tanaka H. Ann Rheum Dis 2022;81:e50.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Yamamoto M, Yoshikawa N, Tanaka H. Efficacy of dupilumab reveals therapeutic target for IgG4-related disease: simultaneous control of inflammation and fibrosis. Ann Rheum Dis 2022;81:e50.
PMID: 32033936